Nebulized myo-Inositol increases oxygen saturation and relieves symptoms in patients with airways diseases
International Journal of Medical Device and Adjuvant Treatments · 2021-09 · 4
DOI: 10.32113/ijmdat_20219_356 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Medical Device and Adjuvant Treatments, 2021-09. Verfasst von A. Spiga. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
OBJECTIVE: Recent findings have evidenced the beneficial activity of myo-Inositol (myo-Ins) for the treatment of airways diseases. The study was designed to examine its efficacy in counteracting respiratory diseases complications, using nebulization as delivery route. PATIENTS AND METHODS: 15 patients with different clinical features of airways diseases were treated for 15 days on average with nebulized myo-Ins. Peripheral capillary oxygen saturation (SpO2) levels and symptoms distribution were analyzed. RESULTS: All the patients experienced a significant increase in the SpO2 levels after the treatment with nebulized myo-Ins [98% (IQR 95-97.5) after the treatment vs. 96% (IQR 98-98) before the treatment] (p
Schlagwörter
Zitieren
APA
Spiga, A. (2021). Nebulized myo-Inositol increases oxygen saturation and relieves symptoms in patients with airways diseases. International Journal of Medical Device and Adjuvant Treatments, 4. https://doi.org/10.32113/ijmdat_20219_356
Vancouver
Spiga A. Nebulized myo-Inositol increases oxygen saturation and relieves symptoms in patients with airways diseases. International Journal of Medical Device and Adjuvant Treatments. 2021;4. doi:10.32113/ijmdat_20219_356
BibTeX
@article{Spiga2021,
author = {Spiga, A.},
title = {Nebulized myo-Inositol increases oxygen saturation and relieves symptoms in patients with airways diseases},
journal = {International Journal of Medical Device and Adjuvant Treatments},
year = {2021},
volume = {4},
doi = {10.32113/ijmdat_20219_356}
}
EUVIMED